Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease

• Published in: Cell stress & chaperones Vol. 19; no. 2; pp. 173 - 181
• Main Authors: Eter, Eman El, Masri, Abeer Al, Habib, Shahid, Zamil, Hana Al, Hersi, Ahmed Al, Hussein, Fawaz Al, Omran, Mohamed Al
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 01.03.2014; Springer Netherlands; Springer Nature B.V
• Subjects: Ankle Brachial Index; Antioxidants; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - complications; Atherosclerosis - pathology; Atherosclerosis - physiopathology; Biochemistry; Biomarkers - blood; Biomedical and Life Sciences; Biomedicine; Blood plasma; Cancer Research; Case-Control Studies; Cell Biology; Diabetes; Diabetes complications; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - pathology; Diabetes Mellitus, Type 2 - physiopathology; Endothelium, Vascular - metabolism; Endothelium, Vascular - pathology; Endothelium, Vascular - physiopathology; Female; Humans; Immunology; Male; Middle Aged; Neurosciences; Original Paper; Oxidative stress; Peripheral Arterial Disease - blood; Peripheral Arterial Disease - complications; Peripheral Arterial Disease - pathology; Peripheral Arterial Disease - physiopathology; Peripheral artery disease; Peroxiredoxins - blood; Triglycerides; Type 2 diabetes mellitus; Vascular diseases; Endothelial dysfunction; ABI; Oxidative stress; Diabetes; Atherosclerosis; Peroxiredoxins
• ISSN: 1355-8145; 1466-1268; 1466-1268
• DOI: 10.1007/s12192-013-0442-y

Peroxiredoxins, a group of antioxidant protein enzymes (PRDX1 to 6), are reported as antiatherogenic factors in animals; however, human studies are lacking. The present work aims to provide baseline data regarding the phenotype of PRDX1, 2, 4, and 6 in diabetic patients with peripheral atherosclerosis disease (PAD) and their relation to endothelial dysfunction (ED) and disease severity. Plasma levels of PRDX1, 2, 4, and 6 and markers of endothelial dysfunction (ICAM-1 and VCAM-1) were measured using ELISA in 55 type 2 diabetic patients having PAD and 25 healthy subjects. Anklebrachial index (ABI), body mass index (BMI), triglycerides (TG), total cholesterol, HbA1c, and insulin resistance (HOMA IR) were measured. PRDX1, 2, 4, and 6 levels were significantly higher in patients compared to controls (PRDX1 21.9±5.71 vs 16.8±3.9 ng/ml, P<0.001, PRDX2 36.5±14.83 vs 20.4±8.61 ng/ml, P<0.001, PRDX4 3,840±1,440 vs 2,696±1,972 pg/ml, P<0.005, PRDX6 311±110 vs 287.9±-114 pg/ml, P<0.05). PRDX1 and PRDX4 correlated negatively with ABI (r=-0.273, P<0.05 and r=-0.28, P<0.05, respectively), while PRDX1 and PRDX2 correlated positively with HOMA/IR and TG (r=0.276, P<0.01 and r=0.295, P<0.01, respectively). ICAM-1 was associated with PRDX2 and log PRDX6 (r=0.345, P=0.0037 and r=0.344, P=0.0038). Our results provide strong links among PRDXs, ED, and severity of PAD in diabetic patients which warrants further evaluation to clarify whether high circulating levels of PRDXs are a consequence of chronic atherosclerotic disease or a predisposing factor for later cardiovascular events.